

Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis

Kang-Ling Wang,¹ Pao-Hsien Chu,^{2*} Cheng-Han Lee,³ Pei-Ying Pai,⁴ Pao-Yen Lin,⁵ Kou-Gi Shyu,⁶ Wei-Tien Chang,⁷ Kuan-Ming Chiu,⁸ Chien-Lung Huang,⁹ Chung-Yi Lee,¹⁰ Yen-Hung Lin,¹¹ Chun-Chieh Wang,¹² Hsueh-Wei Yen,¹³ Wei-Hsian Yin,⁹ Hung-I Yeh,¹⁴ Chern-En Chiang,¹ Shing-Jong Lin¹⁵ and San-Jou Yeh^{2*}

Deep vein thrombosis (DVT) is a potentially catastrophic condition because thrombosis, left untreated, can result in detrimental pulmonary embolism. Yet in the absence of thrombosis, anticoagulation increases the risk of bleeding. In the existing literature, knowledge about the epidemiology of DVT is primarily based on investigations among Caucasian populations. There has been little information available about the epidemiology of DVT in Taiwan, and it is generally believed that DVT is less common in Asian patients than in Caucasian patients. However, DVT is a multifactorial disease that represents the interaction between genetic and environmental factors, and the majority of patients with incident DVT have either inherited thrombophilia or acquired risk factors. Furthermore, DVT is often overlooked. Although symptomatic DVT commonly presents with lower extremity pain, swelling and tenderness, diagnosing DVT is a clinical challenge for physicians. Such a diagnosis of DVT requires a timely systematic assessment, including the use of the Wells score and a D-dimer test to exclude low-risk patients, and imaging modalities to confirm DVT. Compression ultrasound with high sensitivity and specificity is the front-line imaging modality in the diagnostic process for patients with suspected DVT in addition to conventional invasive contrast venography. Most patients require anticoagulation therapy, which typically consists of parenteral heparin bridged to a vitamin K antagonist, with variable duration. The development of non-vitamin K oral anticoagulants has revolutionized the landscape of venous thromboembolism treatment, with 4 agents available, including rivaroxaban, dabigatran, apixaban, and edoxaban. Presently, all 4 drugs have finished their large phase III clinical trial programs and come to the clinical uses in North America and Europe. It is encouraging to note that the published data to date regarding Asian patients indicates that such new therapies are safe and efficacious. Ultimately, our efforts to improve outcomes in patients with DVT rely on the awareness in the scientific and medical community regarding the importance of DVT.

Key Words: Anticoagulants • Deep vein thrombosis • Diagnosis • Treatment

Received: September 8, 2015 Accepted: December 28, 2015

¹General Clinical Research Center, Taipei Veterans General Hospital; School of Medicine, National Yang-Ming University; ²Division of Cardiology, Department of Internal Medicine, Heart Failure Center, Healthcare Center, Chang Gung Memorial Hospital; College of Medicine, Chang Gung University; ³Department of Internal Medicine, National Cheng Kung University Hospital; College of Medicine, National Cheng Kung University; ⁴Division of Cardiology, Department of Internal Medicine, China Medical University Hospital; School of Medicine, China Medical University; ⁵Division of Cardiovascular Surgery, Department of Surgery, National Cheng Kung University Hospital; ⁶Division of Cardiology, Shin Kong Wu Ho-Su Memorial Hospital; ⁷Department of Emergency Medicine, National Taiwan University Hospital; ⁸Division of Cardiovascular Surgery, Cardiovascular Center, Far Eastern Memorial Hospital; ⁹Division of Cardiology, Department of Internal Medicine, Cheng Hsin General Hospital; ¹⁰Department of Cardiovascular Surgery, Department of Surgery, Tri-Service General Hospital; ¹¹Department of Internal Medicine, National Taiwan University Hospital; ¹²Department of Cardiology, Chang Gung Memorial Hospital; College of Medicine, Chang Gung University; ¹³Division of Cardiology, Department of Internal Medicine; Kaohsiung Medical University Hospital; ¹⁴Division of Cardiology, Department of Internal Medicine, Mackay Memorial Hospital; Mackay Medical College; ¹⁵Department of Medical Research, Taipei Veterans General Hospital; School of Medicine, National Yang-Ming University.

Address correspondence and reprint requests to: Dr. Pao-Hsien Chu, Division of Cardiology, Department of Internal Medicine, Heart Failure Center, Healthcare Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan. Tel: 886-3-328-1200 ext. 8162; Fax: 886-3-327-1192; E-mail: taipei.chu@gmail.com

*Pao-Hsien Chu and San-Jou Yeh share equal contribution as corresponding authors.

INTRODUCTION

Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a significant healthcare burden worldwide. For the past 150 years, DVT and PE have been categorized as two separate entities but share a common pathogenesis centered on Virchow's triad of blood flow stasis, vessel wall damage and increased blood viscosity. Actually, both conditions are related aspects of the same dynamic disease process, VTE, that not only share risk factors and treatment but also require a coordinated approach to make the timely diagnosis.¹ In particular, VTE may be lethal as PE may result in acute right ventricular failure.²⁻⁴ In Europe, it has been estimated that more than 500,000 deaths per annum are attributable to VTE or its associated complications.⁵ Besides the high fatality rate, VTE also has features of high recurrence rate,^{6,7} and intractable thrombogenesis that may cause severe chronic sequela,^{8,9} as well as poor patient quality of life.¹⁰ The serious and chronic nature of VTE requires considerable healthcare resources to be properly managed.^{11,12} Furthermore, VTE is predominantly a disease that affects the elderly.¹³ In fact, the incidence rates of VTE increase exponentially as the patient population increases in age.^{14,15} In addition, hospitalized patients undergoing major surgery and patients with acute exacerbations of a variety of medical conditions are at an increased risk for VTE.¹⁶⁻¹⁸ Since a greater proportion of frail elderly patients have either complex medical or surgical conditions, it is expected that an ever-increasing number of patients would be diagnosed with VTE in their coming years.^{19,20}

Clinically, it has been long postulated that PE is a sequel of DVT as clots, forming in the lower extremity or pelvic veins, break off and travel into the pulmonary circulation.²¹ Indeed, more than 40% of patients with DVT have asymptomatic PE identified by imaging studies,^{1,22} and the majority of patients with fatal PE have demonstrable DVT on autopsy, mostly asymptomatic before death.²³ Even though DVT and PE are part of the same disease, VTE, early mortality rates are considerably different,^{14,24,25} particularly a small proportion of patients with PE have substantially worse outcomes within the first 3 months.^{2,26} Therefore, the clinical assessment, the diagnostic and therapeutic approaches for PE and DVT

are manifestly different.⁴

In this document, experts have reviewed the updated information of DVT regarding epidemiology, diagnostic approaches, and pharmacological management. Ultimately, this document has made consensus recommendations for clinical practices. With these renewed efforts, we hope to remind the medical community of VTE as a mitigable disease that has been long overlooked.

EPIDEMIOLOGY

VTE is a common clinical condition in Western countries, with an incidence of 100 cases or greater in 100,000 person-years.^{5,14,25,27} In general, incident symptomatic DVT occurs twice as frequently as incident symptomatic PE.^{28,29} Among patients with lower extremity DVT, regardless of symptoms, isolated distal DVT without concomitant proximal extension represents the majority of all diagnoses with this illness.³⁰⁻³² However, most of the patients with symptomatic DVT also have extensive and proximal thrombosis.³³

Studies conducted in various communities have reported that the incidence of DVT ranged from 93-124 cases per 100,000 person-years in West Europe,^{25,34} 116 cases per 100,000 person-years in North America,⁶ and 52-55 cases per 100,000 person-years in Australia and New Zealand.^{35,36} It has been generally perceived that VTE, including DVT, is less common in Asian patients than in Caucasian patients.^{36,37} The studies conducted in Asia, primarily in ethnic Chinese populations, consistently reported lower incidences of VTE in Asian patients with rates on average four-fold or more lower than in Caucasian patients.³⁸ The average incidences were 17, 12, and 6 cases per 100,000 person-years for VTE, DVT, and PE, respectively.³⁸ However, the information was comparable to data obtained in patients of Asian ethnicity who lived in Western countries.^{36,37} The reported incidence of VTE among the general population in Taiwan was 16-17 cases per 100,000 person-years.^{15,39} However, comparisons between Asian and Western data should be interpreted cautiously. Owing to the frequently stealthy nature of VTE, the diagnosis requires an elevated level of awareness both from patients and physicians, in conjunction with the comprehensive approaches and the sensitivity and specificity of

diagnostic modalities. The long-time belief that VTE is less common in Asian populations may have provided false reassurance and leads to a lack of awareness.⁴⁰ It remains unknown to what extent that the observed differences between Asian and Caucasian patients are genuine or reflect discrepancies between study designs, patient demographics, and physician practices. In addition, population-base epidemiology data has demonstrated yearly increases in incident VTE in Asian patients,²⁰ particularly in high-risk and elderly patients.^{39,41}

Risk factors

DVT, as part of the continuum of VTE, is a multifactorial disease that represents the interaction of genetic and environmental factors. The majority of patients with incident or recurrent VTE have at least one recognized risk factor.^{42,43} Common risk factors are listed in Table 1. Acquired risk factors are far more common than inherited thrombophilia. Additionally, advanced age, cancer, immobilization, recent trauma or surgery, and hospitalization are all important risk factors.^{44,45}

Orthopedic surgery

Major orthopedic surgeries such as hip fracture repair and total hip/knee arthroplasty, including replacement surgery, represent a substantially high risk for VTE.¹⁹ Prior to the 1980s, while no thromboprophylaxis was conducted, the rates of symptomatic VTE in patients after hip fracture surgery without prophylaxis ranged from 15 to 30%.⁴⁶ In the modern era, with thromboprophylaxis in Western populations, symptomatic VTE in patients undergoing major orthopedic surgery was 2.7%, of which 1.5% had DVT.⁴⁷ However, it should be noted that the asymptomatic DVT confirmed by venograms was 3 times higher than symptomatic DVT.⁴⁸ Recent meta-analysis also suggested that asymptomatic DVT accounted for most of the events in patients after knee arthroplasty.⁴⁹

Customarily, it has been perceived that Asian patients are at a lower risk for VTE following orthopedic procedures.⁵⁰ However, evidence supporting an underestimated incidence of VTE in Asia stems from the review of postoperative VTE reported in Asian countries.^{40,51,52} Overall, the adjusted incidences of total DVT were 13%, 16%, 50%, and 18% for general surgery, total

hip replacement, total knee replacement, and hip fracture surgery, respectively.⁴⁰ Regardless of the methodologies used for diagnosing DVT, the reported incidences of post-operative DVT were notably high across Asian countries.⁵¹ The SMART study was a prospective investigation of the incidence of symptomatic VTE up to 1 month postoperative in Asia.⁵³ Patients undergoing major orthopedic surgery without thromboprophylaxis were included, and patients from Taiwan were jointly enrolled in the study.⁵⁴ Among 2,420 Asian patients, postoperative symptomatic DVT occurred in 0.9% of patients; whereas in 326 evaluable venograms, 35.6% of patients had asymptomatic DVT.⁵⁴ The AIDA program also showed a similar result to the SMART venography study. Asian patients undergoing total knee replacement had the highest risk for incident DVT.⁵⁵ Findings of the SMART and AIDA studies were consistent with Western data.⁴⁰ Some studies based upon claims data inferred that the incidence of symptomatic VTE after knee or hip arthroplasty was low in Taiwan.^{56,57} However, a single hospital report based on routine postoperative venograms indicated that 63.6% of patients with total knee arthroplasty had DVT, of which the majority were symptomatic distal DVT.³² The risk of late DVT and thrombosis propagation was similar in patients in Taiwan with isolated distal DVT, or a more complicated DVT.⁵⁸ Apparently, further research is needed to elucidate those discrepancies.

Table 1. Risk factors for venous thromboembolism

Advancing age
Obesity
Recent surgery (including hip or knee replacement)
Major trauma (including fracture)
Active cancer
Acute medical illnesses (e.g. heart failure, respiratory failure)
Paralytic stroke or immobilization
Antiphospholipid syndrome
Inherited thrombophilia
Previous venous thromboembolism
Congenital venous malformation
Varicose veins
Central venous catheter or vena cava filter
Long-distance travel
Pregnancy/antepartum
Oral contraceptives or hormone replacement therapy
References ^{19,21,45}

Medical illness

VTE is also a common complication in patients who suffer critical illness.⁵⁹ In Europe and North America, VTE occurred in 14.9% of patients hospitalized for acute illness without thromboprophylaxis, of which 4.9% had proximal DVT on venograms.⁶⁰ Symptomatic DVT represented only 10% of the total number of asymptomatic events in patients with acute medical illness.⁶¹ The risk of asymptomatic DVT, including both proximal and distal DVT, proven by venograms was as high as 9.0%.⁶² Nevertheless, prospective observations in Asian countries indicated that the rate of symptomatic VTE without thromboprophylaxis in hospitalized non-surgical patients was 1.1%,⁶³ which was comparable to rates in Western populations.⁶⁴

In addition, most of Asian patients were not assigned with thromboprophylaxis measures in the setting of acute illness or surgical conditions. The low reported incidence of symptomatic VTE may only reflect a reduced awareness by patients and physicians. Finally, autopsy data suggested a similar incidence of PE in Asia and in the West.⁶⁵⁻⁶⁷ Some of the apparent differences in the incidence of symptomatic VTE between Western and Asian populations probably arose from variations in access to healthcare.⁶⁸

Inherited thrombophilia

The common inheritable factors for thrombophilia include factor V Leiden, prothrombin G20210A, and deficiencies of natural inhibitors.^{21,44,69} Factor V Leiden and prothrombin G20210A are more prevalent in Caucasians,^{70,71} whereas protein S deficiency is the most com-

mon defect, followed by protein C and antithrombin deficiency in Asians.⁴⁰ In Taiwan, factor V Leiden and prothrombin genetic mutations are rare conditions; the most common inherited thrombophilia is protein S deficiency regardless of the presence of VTE.⁷²⁻⁷⁵ The ethnic differences in the distribution of genetic predisposition to VTE are shown in Table 2.

It is important to realize the limitations of thrombophilia testing. Diagnosing a heritable thrombophilia has rarely changed the course of patient management. The presence of a heritable thrombophilia increases the risk of first thrombosis in varying degrees,²¹ and it does not strongly predict the risk of recurrence after discontinuation of anticoagulation in unselected VTE patients.^{19,76,77} It is generally recommended not to offer heritable thrombophilia testing to patients with provoked VTE.⁷⁸ In NICE recommendations, the only clear indications to perform heritable thrombophilia testing are when consideration is given to discontinuing anticoagulation following an unprovoked VTE, and for patients with a history of a first-degree relative with VTE.⁷⁹

Recommendations

- Asian patients might have a lower risk for symptomatic VTE compared with Caucasian patients.
- Thromboprophylaxis should be incorporated into the daily care regimen for Asian patients complicated with high-risk medical or surgical conditions.
- Factor V Leiden and prothrombin G20210A mutation are rare in Asian patients with VTE, and therefore should not be routinely tested.

Table 2. Ethnic differences in the distribution of inherited thrombophilias

	Factor V Leiden	Prothrombin G20210A mutation	Protein S deficiency	Protein C deficiency	Antithrombin deficiency
General populations, %					
Caucasians	4.8 ⁷¹	2.0, ⁷¹ 2.7 ⁴⁰	0.03-0.13 ⁴⁰	0.2-0.4 ⁷¹	0.02-0.16 ⁷¹
Asians	0-0.2 ⁴⁰	0-0.2 ⁴⁰	0.06-3.7 ⁴⁰	0.3-1.1 ⁴⁰	0-2.3 ⁴⁰
Taiwanese	NA	NA	6.4 ⁷⁴	4.0 ⁷⁴	6.4 ⁷⁴
Patients with VTE, %					
Caucasians	18.8 ⁷¹	7.1 ⁷¹	2.3 ⁷¹	3.7 ⁷¹	1.9 ⁷¹
Asians	0 ⁴⁰	0 ⁴⁰	10.7-17.8 ⁴⁰	8.9-10.7 ⁴⁰	4.7-8.1 ⁴⁰
Taiwanese	0 ^{72,73,75}	0 ⁷³	3.6, ⁷⁵ 8.0, ⁷³ 32.9, ⁷² 33.6 ⁷⁴	4.0, ⁷³ 10.7, ⁷⁵ 17.2, ⁷⁴ 18.8 ⁷²	3.5, ⁷² 4.0, ⁷³ 5.2, ⁷⁴ 7.1 ⁷⁵

NA, not applicable; VTE, venous thromboembolism.

Diagnosis

Venous thrombosis in the lower extremity can involve the superficial leg veins, the deep veins of the calf, and proximal veins, that include popliteal, superficial femoral, common femoral, and iliac veins. DVT at the calf is generally asymptomatic as complete dissolution of small thrombi occurs quite frequently.³⁰ These thrombi can extend proximally and become dangerous, whereas more proximal DVT results in symptoms associated with venous outflow obstruction, venous or perivascular inflammation, or PE.^{80,81}

Diagnosing DVT is an ongoing clinical challenge for physicians. The accurate and timely diagnosis of this disease is mandatory in patients with suspected DVT because thrombi left untreated can result in detrimental PE, whereas anticoagulation in the absence of thrombosis is medically inappropriate. Common symptoms such as pain, swelling and tenderness make it sometimes difficult to distinguish DVT from other medical conditions such as heart failure, local infection, or the popliteal cyst.^{82,83} As a result, the clinical diagnosis of DVT has been proven to be surprisingly unreliable.⁸⁴

Contrast venography

Contrast venography is the benchmark for diagnosing DVT.⁸⁰ The diagnosis is established based on the presence of a constant intraluminal filling defect on at least two projections. Treatment with anticoagulants could be safely withheld in patients with a technically adequate normal venogram, and only 1.3% of patients developed symptomatic DVT within 3 months.⁸⁰ However, venography is invasive, not uniformly available, and has limitations for patients with renal insufficiency and allergic reactions to contrast medium. To illustrate the entire venous drainage of the lower extremity, a dorsal foot vein cannulation is necessary. The technical difficulties frequently encountered have been cannulation failure,⁸⁵ and inadequate visualization of a venous segment.⁸⁶

A certain and reliable diagnosis of DVT can only be established by means of imaging. On the other hand, ruling out acute DVT can be safely achieved by using a standardized clinical probability assessment and a D-dimer blood test. The main advantage of such an approach is the reduction in the required number of imag-

ing tests, which are in general time consuming, costly and associated with radiation exposure and other complications. Therefore, venography is currently seldom used, but still serves as a reference standard and should be used if other tests are unable to definitely confirm or exclude the diagnosis of DVT.⁸⁷

Clinical assessment

An important first step is to assess the patient's pre-test probability of DVT based on medical history and physical examination. Although several structured clinical probability scoring systems have been developed to stratify patients,⁸⁸⁻⁹¹ the system that has been most extensively studied and widely used is the Wells score.⁸⁴ This scoring system, which incorporates medical history and physical examination, is listed in Table 3. The rule that originally categorizes patients as having a low, moderate, or high probability of DVT has been extensively validated by more than 8,000 patients.^{92,93} A simplified version of the Wells score dichotomizes patients as being unlikely (prevalence of DVT: 6%), or likely (prevalence of DVT: 28%) to have DVT for practical purposes.⁹⁴ It has been shown that the Wells scoring system has excellent interobserver reliability, regardless of the extent of physician experience.^{84,95} However, except for Japanese population, the Wells score has not yet been extensively validated in Asian populations.⁹⁶

When an extensive clinical history of the patient has

Table 3. MIB-PEDVT-HO2 acronym for Wells prediction rules for diagnosing deep vein thrombosis

Clinical characteristics	Points
M alignancy, active	+1
I mmobilization of the lower extremities or paralysis	+1
B ed rest > 3 days or major surgery < 12 weeks	+1
P itting edema confined to the symptomatic leg	+1
E ngorgement of entire leg	+1
D iameter difference on affected calf > 3 cm	+1
V eins (superficial, nonvaricose) dilation of the affected leg	+1
T enderness along the distribution of the deep veins	+1
H istory of deep vein thrombosis	+1
O ther diagnoses at least as likely as deep vein thrombosis	-2

Three-level clinical probability (low, ≤ 0 ; intermediate, 1-2; high, ≥ 3) and two-level clinical probability (unlikely, < 2 ; likely, ≥ 2).

Reference^{84,92,94}

been obtained, the clinician can get confirmation of whether any instances of active cancer (**M**alignancy), paraplegia that leads to immobilization (**I**mmobilization of the lower extremities or paralysis), and prolonged bed rest or a recent major surgery (**B**ed rest > 3 days or major surgery < 12 weeks) are major risk factors for DVT and thus related to the patient's course of disease. The presentation indicative of DVT includes leg swelling (**P**itting edema confined to the symptomatic leg and/or **E**ngorgement of the entire leg, and a **D**iameter difference on the affected calf > 3 cm), visible collateral circulation (**V**eins, nonvaricose superficial dilation of the affected leg), and leg pain (**T**enderness along the distribution of the deep veins). A prior history of DVT (**H**istory of deep vein thrombosis) is also an independent risk factor. Finally, if there is an alternative tentative diagnosis other than DVT (**O**ther diagnoses at least as likely as deep vein thrombosis), the likelihood of DVT is decreased. In this instance, the acronym MIB-PEDVT-HO2 is a convenient tool.

D-dimer

The major criticism in using the Wells score to assess DVT probability is the subjective element of considering an alternative diagnosis. This clinical probability can be subsequently supplemented by the combination with a determination of the level of D-dimer for better risk stratification.⁹⁴

Fibrin D-dimer is the degradation product of cross-linked fibrin. D-dimer levels are typically elevated in patients with acute thrombosis because of simultaneous activation of coagulation and fibrinolysis. The sensitivity of an elevated level of D-dimer is high, but the specificity is rather moderate.⁹⁷ A high D-dimer level is also observed in conditions such as malignancy, infection, pregnancy, post surgery or trauma, and increasing age. Consequently, a negative result can facilitate the exclusion of VTE.⁹⁸

A number of D-dimer assays are available. The meta-analysis of 217 D-dimer tests evaluated for DVT indicated that the sensitivities of the D-dimer enzyme-linked immunofluorescence assay, microplate enzyme-linked immunosorbent assay and latex quantitative assay are 96%, 94%, and 93%, respectively; they are superior to those of the whole-blood D-dimer assay, latex semi-quantitative assay and latex qualitative assay as the sensitivities are 83%, 85%, and 69%, respectively.⁹⁹ The higher

sensitivity yields a higher negative predictive value and introduces fewer concerns regarding false-negative results. In addition, the age-dependent decrease in specificity of D-dimer with suspected PE was observed.¹⁰⁰ Recent investigations suggested that age-adjusted cut-offs (age × 10 ug/L above 50 years) improved specificity of D-dimer testing in the elderly with suspected PE.¹⁰¹⁻¹⁰³ The European guidelines have adopted the age-adjusted D-dimer cut-offs for the diagnosis of acute PE.⁴ The clinical application of the aforementioned aspect regarding D-dimer testing has not been prospectively validated in patients with suspected DVT and not yet endorsed by American guidelines for the diagnosis of DVT.

Compression ultrasound

Compression ultrasound (CUS) is the front-line imaging modality in the diagnostic process for patients with suspected DVT. The sensitivity and specificity of the CUS in diagnosing proximal DVT is 94% and 98%, respectively.¹⁰⁴ However, the sensitivity decreases in detecting asymptomatic proximal DVT with similar specificity.¹⁰⁵ The sensitivity of CUS in diagnosing distal DVT is relatively low, at 57%,¹⁰⁴ and is only 48% for detecting asymptomatic calf vein thrombosis.¹⁰⁵ For proximal DVT, ultrasound studies have a positive predictive value of 100% and 71% for symptomatic and asymptomatic events, respectively, whereas the negative predictive value for symptomatic and asymptomatic events are 100% and 94%, respectively.¹⁰⁶

Conventionally, 3 protocols are presently available. The proximal CUS (so-called 2-point CUS) assesses compressibility of the femoral and popliteal veins. Loss of compressibility of either segment is diagnostic for incident proximal DVT. The second approach is to conduct a complete CUS along the proximal till distal deep veins of the leg. The prior study suggested that only 0.5% of patients withholding anticoagulation after a single, negative, complete CUS had distal DVT within 3 months and no proximal DVT occurred.⁸² Although it has good accuracy, complete CUS is time consuming and a modest proportion of imaging results are inadequate, particularly in the calf veins.¹⁰⁷ As an alternative to the aforementioned measures, repeated proximal CUS after 5-7 days is recommended in patients with an initial negative proximal CUS finding. This approach detects if any distal DVT propagates into the proximal vein that may increase

the risk of PE. The repeated proximal CUS strategy in the intermediate to high-risk patients is safe with regard to withholding anticoagulation.^{108,109}

Computed tomography and magnetic resonance imaging

Both computed tomography venography (CTV) and magnetic resonance venography (MRV) are alternatives to CUS as a means to diagnose DVT.¹¹⁰ In particular, CTV provides direct imaging of the inferior vena cava, pelvic and lower extremity veins immediately after computed tomography pulmonary angiography. Since DVT is the most important risk for PE, it seems ideal that a single examination simplifies and shortens VTE work-up. However, this single comprehensive imaging modality for VTE requires a larger amount of iodinated contrast medium to produce adequate opacification of the pulmonary arteries, and pelvic and lower extremity veins,^{111,112} and exposure to ionizing radiation may be greater than for either test alone.^{113,114} The pooled analysis showed that for the diagnosis of DVT, in particular proximal DVT, CTV had a sensitivity and specificity of 96% and 95%, respectively.¹¹⁵ In addition, to facilitate the diagnosis of DVT, MRV has a sensitivity and specificity of 92% and 95%, respectively, and the sensitivity for the diagnosis of proximal DVT increases to 94%.¹¹⁶

The sensitivity and specificity of both CTV and MRV for the diagnosis of DVT are comparable to CUS. However, the safety of withholding anticoagulation on the basis of a normal CTV or MTV result has yet to be evaluated prospectively. Furthermore, CTV has generally been tested along with computed tomography pulmonary angiogram in patients with suspected PE. CTV, however, has yet to be more extensively assessed as a standalone diagnostic modality in patients with suspected DVT. Therefore, both imaging modalities should not be routinely used as front-line approaches.⁸⁷ It is reasonable to utilize CTV or MRV in conditions that CUS cannot be performed or is less reliable, such as for patients with morbid obesity or casts, and patients with suspected DVT in the iliac or inferior cava vein or suspected venous anomaly.^{87,98,117}

Recommendations

- To diagnose DVT requires systematic assessment (Figure 1).
- An acronym of MIB-PEDVT-HO2 for the Wells score is the comprehensive initial to stratify patients.
- The combination of the Wells score and a D-dimer test is validated in deciding whether to initially withhold anticoagulation.
- CUS, either proximal, whole leg or repeated measure-




Figure 1. Diagnosis flowchart. * Moderately or highly sensitive D-dimer test.

ments, should constitute the first-line imaging for most patients with the increased likelihood of DVT.

- CTV and MRV have similar sensitivities and specificities to CUS in diagnosing DVT. However, those measures should be reserved for conditions where patients cannot be evaluated properly by CUS or thrombosis in pelvic veins, or inferior vena cava is suspected.
- Contrast venography is the reference modality for diagnosing DVT and is reserved for occasions when other tests are unable to definitely establish or exclude DVT.

Treatment

DVT can become complicated with PE, and has a high recurrence at the early stage without treatment.¹¹⁸ The risk of recurrence and post-thrombotic syndrome (PTS) develop steadily after the first episode of DVT.^{7,119} The most effective manner in which to prevent thrombus extension, recurrence and late complications primarily depends on effective pharmacological and/or mechanical treatment.¹²⁰

Thrombolysis

Despite effective anticoagulation, only 20%, 39% and 58% of the patients had normal CUS at 3 months, 6 months and 1 year, respectively.¹²¹ Other studies reported a similar rate of the presence of residual thrombus at 3 months and beyond.^{122,123} The presence of residual thrombus has been associated with the risk of recurrence and the occurrence of PTS.^{121,124,125} The possibility to reduce thrombus burden and to restore venous drainage in the early stage of DVT in patients with extreme high risk for thromboembolism complications is an appealing one. The evidence suggested that systemic thrombolysis had the potential to reduce PTS at the expense of an increase in major bleeding. As a result, systemic thrombolysis is not generally recommended by the current guidelines.^{120,126} A variety of endovascular interventions have been tested in patients with iliofemoral DVT, including catheter-directed thrombolysis (CDT) and/or thrombectomy. CDT reduces PTS at 24 months with a number needed to treat of 7 in a randomized trial that involved 209 patients with iliofemoral DVT.¹²⁷ There was no significant reduction in recurrence by CDT in this small-sized trial. However, bleeding is a

primary concern of a broad application of thrombolysis.¹²⁸ Currently, CDT is preferred for patients with iliofemoral DVT and/or limb-threatening circulatory compromise, acute or subacute symptoms, and a low risk of bleeding.^{120,126}

Endovascular thrombectomy and stenting have reduced recurrence and PTS at 30 months compared with anticoagulation only in a randomized trial involving 169 patients with proximal DVT.¹²⁹ Whether pharmacomechanical CDT truly reduces recurrence and PTS in patients with proximal DVT is being evaluated currently in a larger trial with a target of more than 600 patients and a primary endpoint of PTS occurrence.¹³⁰

Conventional anticoagulation

The initial and standard pharmacological approach in patients with DVT started with parenteral anticoagulants, either unfractionated or low-molecular-weight heparin, followed by long-term vitamin K antagonists (VKAs). The importance of effective initial parenteral anticoagulants has been emphasized by the results in early trials.^{131,132} It has been suggested to start parenteral anticoagulation within a short period of time while waiting for the results of diagnostic tests in patients with intermediate to high clinical suspicion of acute DVT.¹²⁰ In general, twice-daily low-molecular-weight heparin (LMWH) administration is preferred over once-daily LMWH administration or unfractionated heparin for a lower risk of inducing major bleeding and heparin-induced thrombocytopenia.^{133,134}

An oral VKA is preferably initiated on the same day as the start of parenteral anticoagulants, which should be continued for at least 5 days until the international normalized ratio (INR) is 2.0 or above for 2 consecutive days.^{120,135} The targeted INR for VKA treatment is 2.0-3.0. The subtherapeutic dose is associated with higher recurrence,¹³⁶ and the occurrence of PTS.¹³⁷ To maintain adequate anticoagulation without an excessive risk of bleeding in the use of VKAs, primarily warfarin, is a lesson that every clinician has learned for the past 50 years due to the limitations of new effective treatment.¹³⁸

Non-vitamin K oral anticoagulants (NOACs)

NOACs have been developed to optimize VTE management and overcome the limitations of traditional treatments. Five NOACs have been extensively tested in patients with VTE in clinical trials. Except for ximela-

gatan, which has been withdrawn, rivaroxaban, dabigatran, apixaban, and edoxaban have been approved in North America and Europe for VTE treatment; edoxaban has completed the largest clinical trial ever in VTE treatment. Except for acute treatment, rivaroxaban, dabigatran, and apixaban have been compared with placebo or warfarin in the setting of extended treatment for VTE.

Rivaroxaban

Patients with acute DVT or PE were enrolled in the EINSTEIN program. In the EINSTEIN DVT, 3,449 patients with acute symptomatic DVT were randomized to receive oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) or subcutaneous enoxaparin followed by warfarin for 3, 6, or 12 months.¹³⁹ In the EINSTEIN PE, 4,832 patients who had acute symptomatic PE with or without DVT, were randomized according to the same protocol.¹⁴⁰ In both the EINSTEIN DVT and EINSTEIN PE, a single-drug approach by rivaroxaban was non-inferior to the standard treatment with regard to VTE recurrence and had no excessive major or clinically relevant nonmajor bleeding.^{139,140} In particular, there was no signal of excessive VTE recurrence by day 21, at the end of the twice-daily treatment. The pool analysis of 8,282 patients showed very similar results of separate trials but there was significantly less major bleeding in patients with rivaroxaban compared to the standard therapy (hazard ratio: 0.54; 95% confidence interval: 0.37-0.79, $p = 0.002$).¹⁴¹

Dabigatran

Dabigatran has been tested in 2 trials for acute VTE treatment (RE-COVER and RE-COVER II).^{142,143} The RECOVER series consisted of 2 trials because of low rate of recurrent VTE observed in the first trial with a small population. Dabigatran 150 mg twice daily was compared with warfarin for 6 months after the initial parenteral heparin. There were 2,564 and 2,589 patients with acute VTE enrolled in the RE-COVER and the RECOVER II, respectively. In both trials, dabigatran was non-inferior to warfarin with regard to recurrent VTE but had significantly less major or clinically relevant nonmajor bleeding (hazard ratio: 0.63; 95% confidence interval: 0.47-0.84, in the RECOVER; hazard ratio: 0.62; 95% confidence interval: 0.45-0.84, in the RECOVER II).

The extent of major bleeding was similar in patients with dabigatran or warfarin. The conclusions were consistent in the pooled analysis.¹⁴²

Apixaban

In the AMPLIFY study, 5,400 patients with acute VTE were randomized to receive apixaban (10 mg twice daily for 7 days, followed by 5 mg twice daily) or subcutaneous enoxaparin followed by warfarin for 6 months.¹⁴⁴ Apixaban, as a single-drug approach, was non-inferior to the standard treatment with respect to recurrent VTE. Both major bleeding or clinically relevant nonmajor bleeding were significantly less in patients with apixaban (relative risk: 0.44, 95% confidence interval: 0.36-0.55, $p < 0.001$; relative risk: 0.31, 95% confidence interval: 0.17-0.55, $p < 0.001$, respectively).

Edoxaban

Edoxaban has been compared with warfarin in the largest phase III clinical trial in VTE treatment. In the HOKUSAI VTE, 8,240 patients with acute VTE were randomly assigned to edoxaban (60 mg once daily or 30 mg once daily in patients with renal impairment or low body weight) or warfarin for 3 to 12 months after the initial parenteral heparin.¹⁴⁵ Edoxaban was non-inferior to warfarin with respect to recurrent VTE. Furthermore, edoxaban had significantly less major or clinically relevant nonmajor bleeding (hazard ratio: 0.81; 95% confidence interval: 0.71-0.94, $p = 0.004$), and had no excessive risk for major bleeding.

The risk of recurrent VTE and bleeding are fundamental considerations for recommendation of VTE management. Although clinical trials of NOACs in VTE treatment have differences with regard to the study designs, the conclusions are rather similar. The design and results of pivotal NOAC trials for VTE treatment are listed in Table 4 and 5. The availability of NOACs that do not require monitoring will create a treatment shift for patients with VTE as an effective, safer, and more convenient treatment for patients, physicians, and healthcare systems.¹⁴⁶ The additional advantage of NOACs against VKAs is that Asians are prone to bleeding when treated with VKAs, and the optimal INR use has yet to be determined in Asian patients.^{147,148} In trials evaluating NOACs for stroke prevention in atrial fibrillation, NOACs have

Table 4. Patient characteristics in clinical trials of non-vitamin K oral anticoagulants for venous thromboembolism treatment

	EINSTEIN-DVT		EINSTEIN-PE		RE-COVER		RE-COVER II		AMPLIFY		HOKUSAI-VTE	
	Rivaroxaban	VKA	Rivaroxaban	VKA	Dabigatran	VKA	Dabigatran	VKA	Apixaban	VKA	Edoxaban	VKA
Number of patients	1,731	1,718	2,419	2,413	1,273	1,266	1,280	1,288	2,691	2,704	4,118	4,122
Design	Open-label		Open-label		Double-blinded		Double-blinded		Double-blinded		Double-blinded	
Treatment duration	3, 6 or 12 months*		3, 6 or 12 months*		6 months		6 months		6 months		3, 6 or 12 months*	
Initial treatment	Rivaroxaban LMWH 15 mg twice daily for 3 weeks	≥ 5 days	Rivaroxaban LMWH 15 mg twice daily for 3 weeks	≥ 5 days	LMWH or UFH ≥ 5 days		LMWH or UFH ≥ 5 days		Apixaban 10 mg twice daily for 7 days	LMWH ≥ 5 days	LMWH or UFH ≥ 5 days	
Long-term treatment	Rivaroxaban 20 mg once daily	INR: 2-3	Rivaroxaban 20 mg once daily	INR: 2-3	Dabigatran 150 mg twice daily	INR: 2-3	Dabigatran 150mg twice daily	INR: 2-3	Apixaban 5mg twice daily	INR: 2-3	Edoxaban 60 mg once daily [#]	INR: 2-3
Age, years	56	56	58	58	55	54	55	55	57	57	56	56
Female, %	43	44	46	48	42	41	39	40	42	41	43	43
Index event, %												
DVT	99	99	0	0	69	69	69	68	65	66	60	60
PE ± DVT	1	1	100	100	31	31	31	32	35	34	40	40
Risk factor, %												
Unprovoked	61	63	65	64	NR	NR	NR	NR	90	90	66	65
Prior VTE	19	19	19	20	26	25	19	16	17	15	19	18
Cancer	7	5	5	5	5	5	4	4	2	3	9	10
TTR, %	NA	58	NA	63	NA	60	NA	57	NA	60	NA	64

* Treatment duration was left to the discretion of the treating physician. [#] An edoxaban 30 mg once daily was administered in certain conditions. DVT, deep vein thrombosis; INR, international normalized ratio; LMWH, low-molecular-weight heparin; NA, not applicable; NR, not reported; PE, pulmonary embolism; TTR, time in therapeutic range; UFH, unfractionated heparin; VKA, vitamin K antagonist; VTE, venous thromboembolism.

Table 5. Hazard ratio (95% confident interval) of selected outcomes for non-vitamin K oral anticoagulants in venous thromboembolism treatment

	Rivaroxaban vs. VKAs EINSTEIN pooled analysis	Dabigatran vs. VKAs RE-COVER pooled analysis	Apixaban vs. VKAs AMPLIFY*	Edoxaban vs. VKAs HOKUSAI-VTE
Recurrent VTE	0.89 (0.66-1.19)	1.09 (0.76-1.57)	0.84 (0.60-1.18)	0.82 (0.60-1.14) [#]
Major bleeding	0.54 (0.37-0.79)	0.73 (0.48-1.11)	0.31 (0.17-0.55)	0.84 (0.59-1.21)
Major or CRNM bleeding	0.93 (0.81-1.06)	0.62 (0.50-0.76)	0.44 (0.36-0.55)	0.81 (0.71-0.94)
Death	0.89 (0.67-1.18)	1.00 (0.67-1.51)	0.79 (0.53-1.19)	1.05 (0.82-1.35)

* Relative risks are reported for the AMPLIFY study. [#] Recurrent VTE during on-treatment period. CRNM, clinically relevant nonmajor; VKA, vitamin K antagonist; VTE, venous thromboembolism.

less critical bleeding than VKAs in Asian patients than in patients with other ethnicities.^{147,149,150} In trials evaluating NOACs for VTE treatment, both rivaroxaban and edoxaban have published data of Asian patients.^{150,151} Both analyses reconfirmed the similar efficacy and the probable safety advantage of rivaroxaban and edoxaban against dose-adjusted VKAs.

Recommendations

- Timely administration of anticoagulation is essential in the treatment of DVT (Figure 2).
- Conventional treatment involves parenteral heparin bridging to VKAs with a maintenance target INR of 2.0-3.0.
- Two strategies have been tested in 6 pivotal trials of




Figure 2. Treatment flowchart.

NOACs for VTE treatment; the single-drug approach using rivaroxaban or apixaban, and the 2-phase approach using parenteral heparin bridged to dabigatran or edoxaban are as effective as the conventional treatment with regard to the recurrence of VTE.

- With respect to major bleeding, NOACs seem to be safer than the conventional treatment.

Duration

A 3-phase anticoagulation treatment is recommended by the current guidelines.¹²⁰ The initial phase of intensified anticoagulants is followed by minimal 3-month long-term oral anticoagulants for the majority of patients.¹⁵²⁻¹⁵⁴ After the first 2 phases, whether patients require an extended phase of anticoagulants depends on balances between risk for VTE recurrence without and bleeding with anticoagulants,¹⁵⁵ and the preference of patients. DVT, as part of VTE, is a chronic disease with a high rate of recurrence. Previous epidemiological data indicated that more than 30% of pa-

tients developed recurrence within 10 years.^{7,119,156,157} In general, the long-term recurrence rate is not extremely different between DVT and PE. Rather, recurrence is more likely to occur in the same clinical manifestation as the index event.^{24,118}

According to the most recent data from randomized trials, the risk of early recurrence (on anticoagulant treatment) is about 1-2%.¹⁵⁸ Factors associated with recurrence are listed in Table 6. Risk factors for recurrence during anticoagulation include immobilization, cancer, and chronic pulmonary condition,⁷⁶ in which immobilization > 3 days is the strongest risk factor.¹⁵⁹ The risk of recurrence after terminating anticoagulant therapy markedly differs depending on whether the initial event is associated with one or more risk factors.^{152,160,161} The long-term recurrence rate has been reported to reach 13% at 1 year, 23% at 5 years, and 30% at 10 years.¹⁶² Risk factors for recurrence after discontinuing anticoagulation include male sex,¹⁶³ elevated body mass index,¹⁶⁴ low levels of high-density lipoprotein chole-

terol,¹⁶⁵ idiopathic presentation, thrombophilia, increasing age, shorter duration of anticoagulation, cancer, and residual thrombus.^{7,121,166}

In fact, the provoked nature of an index event is a major determinant for the risk of VTE recurrence.^{15,167} In patients with proximal DVT and PE, the estimated cumulative risk of recurrence after stopping anticoagulants is as follows: VTE provoked by surgery, 1% after 1 year and 3% after 5 years; VTE provoked by a nonsurgical reversible risk factor, 5% after 1 year and 15% after 5 years; and unprovoked VTE, 10% recurrence after 1 year and 30% after 5 years, and 15% annually for patients with cancer.¹²⁰

Previous trials have compared different antithrombotic strategies in the reduction of VTE recurrence in patients with an unprovoked event.^{152,160,168} These trials indicated that extending anticoagulation for 1 year has yet to eliminate long-term recurrence in patients with unprovoked VTE. Two trials have intended to extend the anticoagulation treatment beyond 1 year.^{169,170} In the ELATE study, low-intensity warfarin (target INR of 1.5-

1.9) has been compared with standard-intensity warfarin (target INR of 2.0-3.0), and patients have been followed for an average of 2.4 years. The recurrence rate was 1.9 per 100 patient-years in the low-intensity group compared with 0.7 per 100 patient-years in the standard-intensity group ($p = 0.03$).¹⁷⁰ In the PREVENT study, 508 patients with unprovoked VTE were randomized to low-intensity warfarin (target INR of 1.5-2.0) or placebo. The trial was terminated after 2 years of therapy due to extreme beneficial effect with warfarin. The recurrent VTE was 2.6 per 100 patient-years with warfarin compared with 7.2 per 100 patient-years with placebo ($p < 0.001$).¹⁶⁹ Incidentally, the major bleeding was remarkable low in both trials (around 1 per 100 patient-years in all treatment groups).

Besides warfarin, extended treatment trials for VTE involving rivaroxaban, dabigatran and apixaban have been completed, with variable treatment duration and comparators.^{139,171,172} All 3 NOACs have largely reduced recurrent or fatal VTE and had no excessive risk for major bleeding compared with placebo. The recurrent or fatal VTE and major bleeding was similar with dabigatran and standard-intensity warfarin, but the risk of major or clinically relevant bleeding event was lower with dabigatran compared with standard-intensity warfarin.¹⁷¹ The information associated with the NOACs trials involving extended treatment for VTE is listed in Table 7.

In addition to anticoagulants, aspirin has been used for VTE prevention in high-risk patients.¹⁷³ Recently, 2 extended treatment trials compared low-dose aspirin (100 mg once daily) with placebo in patients with unprovoked VTE.^{174,175} The pool analysis of 2 trials indicated that the recurrence rate was 5.1% per year with

Table 6. Risk factors for recurrent venous thromboembolism

While taking anticoagulant drugs
Immobilization
Cancer
Chronic obstructive pulmonary disease
After anticoagulant drugs are discontinued
Unprovoked event or associated with cancer
Male sex
Obesity
Lack of recanalization of DVT on venous ultrasound examination
Presence of antiphospholipid antibody
Reference ^{76,152,161,162}

Table 7. Clinical trials of non-vitamin K oral anticoagulants in extended treatment for venous thromboembolism

	Dabigatran		Rivaroxaban	Apixaban	
	RE-MEDY	RE-SONATE	EINSTEIN-EXT	AMPLIFY-EXT	AMPLIFY-EXT
Comparator	Warfarin	Placebo	Placebo	Placebo	Placebo
Treatment	Dabigatran 150 twice daily	Dabigatran 150 twice daily	Rivaroxaban 20 mg once daily	Apixaban 2.5 mg twice daily	Apixaban 5 mg twice daily
Treatment duration	18 months	6 months	6 or 12 months	12 months	12 months
Recurrent VTE*	1.44 (0.78-2.64)	0.08 (0.02-0.25)	0.18 (0.09-0.39)	0.19 (0.11-0.33)	0.20 (0.11-0.34)
Major bleeding*	0.52 (0.27-1.02)	NA	NA	0.49 (0.09-2.64)	0.25 (0.03-2.24)

* Hazard ratio (95% confident interval).

NA, not applicable; VKA, vitamin K antagonist; VTE, venous thromboembolism.

low-dose aspirin compared with 7.5% per year with placebo ($p = 0.008$), whereas there was no excessive risk for major bleeding.¹⁷⁶

Despite the probability that extended treatment is effective and generally safe in reducing VTE recurrence in patients with higher risk for recurrence, anticoagulation treatment of indefinite duration, or even probably for a lifetime, is a major undertaking both for patients and healthcare professionals.¹⁷⁷ The decision of the treatment duration for DVT requires a complex evaluation that balances the risks of recurrence in the absence of anticoagulation against the risks of bleeding complications with continued pharmacological therapy.^{152,178} There is not yet a universally accepted method for predicting the risk of VTE recurrence in the absence of anticoagulation. The DASH scoring system and Vienna prediction model are newly developed assessment for patients with unprovoked VTE.^{179,180} To address the risk of major bleeding with anticoagulation in the first 3 months of treatment, the practice guidelines recommend a complex matrix whereas the RIETE scoring is a simple assessment.¹⁸¹

Recommendations

- The long-term treatment comprises minimally a 3-month duration of oral anticoagulants.
- Patients without a transient reversible risk factor for VTE are more likely to develop recurrences after cessation of anticoagulant treatment.
- For extended treatment, normal or low intensity warfarin, dabigatran, rivaroxaban, apixaban, and aspirin are effective on the reduction of VTE recurrence in patients with unprovoked VTE.
- Whether patients require an extended phase of anticoagulants depends on balances between the risk of VTE recurrence without anticoagulants and bleeding with anticoagulants, and the preference of patients.
- There is not yet a widely accepted scoring system for prediction of VTE recurrence without anticoagulation and bleeding with anticoagulation.

Pregnancy-related VTE

Pregnancy is associated with a hypercoagulable state characterized by increased concentrations of procoagulant factors and by a simultaneous decrease of anticoagulant factors.¹⁸² It is important to note that

the likelihood of VTE is increased at least 4-fold during pregnancy compared with a non-pregnant status, and is a major cause of maternal mortality in the developed world.^{183,184} The overall incidence of VTE in pregnancy is about 1-2 cases per 1,000 deliveries in the West, and around 1 case per 10,000 individuals in Asia.^{20,185} The risk of VTE remains high until the first 6 weeks after delivery have passed.¹⁸⁶ Furthermore, VTE occurs at a rate of 5.4, 7.2, and 4.3 cases per 10,000 pregnancies for antepartum, peripartum, and postpartum, respectively.¹⁸⁵ Isolated DVT, particularly left iliac and/or femoral vein, is more common in pregnant patients due to the enlarged uterus' compressive effects on veins.¹⁸⁷

The use of diagnostic algorithms for DVT, the combination of structured clinical prediction rules and the use of D-dimer testing, in non-pregnant patients is neither adequate nor validated when applied in pregnancy. Leg swelling, the cardinal sign and symptom of DVT, may be associated with a normal pregnancy and levels of D-dimer increase with the progression of a normal pregnancy.¹⁸⁸ The cornerstone of diagnosing DVT in pregnancy is the demonstration of presence of a clot by CUS. Compression maneuvers should be performed along the entire venous system from the femoral to the popliteal vein. The sensitivity and negative predictive value are 90.9% and 98.9%, respectively,¹⁸⁹ with a reduced accuracy for isolated calf- and iliac-vein thrombosis.¹⁹⁰ CUS could be repeated within 7 days if the initial study is negative,^{191,192} or MRV could be used if the initial CUS study is negative or for detecting iliac-vein thrombosis.¹⁹³

It is safe to withhold anticoagulation in pregnant patients with suspected DVT following negative serial CUS and iliac vein imaging.¹⁹⁴ Maternal complications from anticoagulant therapy are similar to those seen in non-pregnant patients.¹⁹⁵ However, additional considerations regarding the health and life of the fetus will affect patients' choices on anticoagulation therapy. For the treatment of acute DVT, particularly proximal DVT with or without PE, inpatient treatment with parenteral heparin is recommended and VKAs should only be considered in exceptional circumstances.^{192,196} Pregnant women were excluded from participating in clinical trials evaluating NOACs, and NOACs are not approved for such conditions and should not be used in breast-feeding pa-

tients. In general, LMWH is recommended over unfractionated heparin for use in pregnant patients. It is reasonable to use the twice-daily regimen of LMWH in pregnancy, especially for the first month when the risk of recurrence is the greatest. This practice also stems from the altered renal elimination of LMWH and the impact of weight gain during pregnancy.

No study has assessed the optimal duration of anticoagulant therapy for treatment of pregnancy-related VTE. In non-pregnant patients with VTE, evidence supports a minimum duration of 3 months of treatment. Major guidelines recommend anticoagulants, which should be continued for at least 6 weeks postpartum (for a minimum total therapy duration of 3 months).^{196,197} And for pregnant women with a prior history of VTE associated with transient risk factors, withholding antepartum anticoagulation therapy is generally safe.^{198,199}

Cancer-related VTE

Patients with cancer are at the increased risk for VTE,²⁰⁰ and carry a substantial risk for VTE recurrence.^{15,201} Meanwhile, VTE can be attributed to major morbidity and mortality in patients with cancer,²⁰² and has a significant negative impact on quality of life in patients with cancer.²⁰³ Although long-term VKAs are warranted and prevent recurrence in the majority of patients, VKA treatment therapy is problematic in patients with cancer because drug interactions, malnutrition, vomiting, and liver dysfunction can lead to unpredictable levels of anticoagulation in addition to the potential need for invasive procedures requiring interruption of VKAs.²⁰⁴ These limitations may contribute to the higher risk of recurrent thromboembolism and bleeding in patients with cancer than in patients without cancer.

Weight-adjusted LMWH as a parenteral agent is effective and appealing for treatment in patients with cancer. The remote and recent clinical trials have demonstrated the advantage of treatment with LMWH over VKAs for 6 months.^{205,206} NOACs had at least a similar clinical benefit as VKAs in the subgroup analyses,^{141,207,208} and might be even comparable to LMWH in the pooled analyses.^{209,210} However, additional studies are needed to confirm this concept and to compare NOACs with LMWH directly in patients with cancer.²¹¹ Currently, 3 protocols that will randomize cancer patients with VTE

to either NOACs or LMWH with a variable treatment duration are approved (NCT02583191, NCT02585713, NCT02073682). Despite practicing guidelines recommending LMWH for at least 3-6 months and possibly indefinitely for patients with active cancer, the optimal duration of LMWH treatment beyond 6 months is yet to be determined by the evidence from the randomized controlled trials.^{212,213} In the Hokusai VTE-cancer study, patients will be treated for an extended period up to 12 months on the basis of the risk-benefit assessment by the treating physician and/or on patient preference.²¹⁴

Areas with uncertainty

Although a large number of cohort studies have provided convincing data, and the clinical assessment pathway has been long constructed, these studies describe and have been validated mainly in Western populations. The therapeutic trials had a very low proportion of both young and elderly patients, and patients with minimal comorbidity. In addition, a small proportion of Asian patients participated in these trials. The NOACs have been tested in extended treatment with limited follow-up periods. It will be necessary to elaborate on (i) whether Asian patients indeed have a low risk for the development of DVT and PE, (ii) whether the diagnostic algorithm is feasible if Asian patients truly have a lower prevalence of DVT and PE, (iii) long-term recurrence without and bleeding risk with anticoagulation treatment in Asian patients, and (iv) whether treatment for VTE in patients with pregnancy or cancer is practical in Asian patients who might have different thrombosis and bleeding profiles. Nevertheless, the accumulation of clinical experience with new therapeutics in the real-world will have to proceed at a prudent pace. For those trials that enrolled but have yet to publish data regarding Asian patients, we welcome public dissemination of the research results, so that physicians, patients, and other health care professionals can benefit from the results.^{215,216}

SUMMARY

The heavy burden of DVT, as part of VTE continuum, is seriously overlooked in Taiwan. Routine risk assess-

ment and thromboprophylaxis for high-risk patient have not been established, and the guidelines are not yet developed. On the other hand, the diagnosis of DVT requires a sophisticated evaluation from pre-test risk assessment until imaging confirmation. The implantation of the comprehensive diagnostic algorithm facilitates the timely administration of therapeutics for the appropriate patients. For patients with DVT, anticoagulation is essential to prevent thrombus extension and recurrence. The conventional strategy of initial parenteral heparin followed by warfarin is effective, but somehow inconvenient and has its limitations. Quickly-adopted NOACs as an alternative strategy for acute VTE treatment have their unique features with respect to each other. Some of the NOACs are taken once daily, others twice daily, some require the use of a parenteral heparin lead in, and others use the single-drug approach. The single-drug approach without preceding parenteral treatments is appealing to low risk outpatients whereas the conventional parenteral lead in strategy is feasible for intermediate/high risk inpatients. Nevertheless, NOACs have been proven effectively safe in the large-scale clinical trials, particularly with respect to the important outcome of bleeding. Finally, DVT is a chronic disease and unprovoked DVT carries a higher risk for recurrence. Extended treatment should be considered in such patients in part based upon the weight of prevention of recurrence and risk of bleeding. Growing studies have paid attention to the idea of constructing a more user-friendly scoring system to predict VTE recurrence without and bleeding events with anticoagulation. Finally, this consensus document hopefully can upsurge the awareness of DVT in the medical community, and improve patient outcomes during the acute phase and thereafter in the long run.

DISCLOSURE

Dr. Kang-Ling Wang received some benefit from Bayer, Boehringer Ingelheim, and Daiichi Sankyo. Dr. Kou-Gi Shyu has been on the speaker's bureau for AstraZeneca, Bayer, Daiichi Sankyo, MSD, Pfizer, Sanofi, and Takeda. Dr. Chern-En Chiang has been on the speaker's bureau for Bayer, Boehringer Ingelheim, Daiichi Sankyo, and Pfizer.

FUNDING SOURCES

This work was supported, in part, by grants from the Ministry of Health and Welfare (MOHW104-TDU-B-211-113-003), the Ministry of Science and Technology (102-2314-B-182A-060-MY2 and 104-2314-B-182A-131), and Chang Gung Memorial Hospital (CIRPG3E0011).

REFERENCES

1. Moser KM, Fedullo PF, Litlejohn JK, Crawford R. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis. *JAMA* 1994;271(3):223-5.
2. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). *Lancet* 1999;353(9162):1386-9.
3. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm Hg or higher. *Arch Intern Med* 2005;165(15):1777-81.
4. Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. *Eur Heart J* 2014;35(43):3033-69.
5. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. *Thromb Haemost* 2007;98(4):756-64.
6. Spencer FA, Gore JM, Lessard D, et al. Patient outcomes after deep vein thrombosis and pulmonary embolism: the Worcester Venous Thromboembolism Study. *Arch Intern Med* 2008;168(4):425-30.
7. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. *Haematologica* 2007;92(2):199-205.
8. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. *N Engl J Med* 2004;350(22):2257-64.
9. Kahn SR. The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis. *J Thromb Thrombolysis* 2006;21(1):41-8.
10. Roberts LN, Patel RK, Donaldson N, et al. Post-thrombotic syndrome is an independent determinant of health-related quality of life following both first proximal and distal deep vein thrombosis. *Haematologica* 2014;99(3):e41-3.
11. Lefebvre P, Laliberte F, Nutescu EA, et al. All-cause and disease-related health care costs associated with recurrent venous thromboembolism. *Thromb Haemost* 2013;110(6):1288-97.

12. Sorensen HT, Horvath-Puho E, Pedersen L, et al. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. *Lancet* 2007;370(9601):1773-9.
13. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. *Arch Intern Med* 1998;158(6):585-93.
14. White RH. The epidemiology of venous thromboembolism. *Circulation* 2003;107(23 Suppl 1): I4-8.
15. Lee CH, Lin LJ, Cheng CL, et al. Incidence and cumulative recurrence rates of venous thromboembolism in the Taiwanese population. *J Thromb Haemost* 2010;8(7):1515-23.
16. Alikhan R, Cohen AT, Combe S, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. *Arch Intern Med* 2004;164(9):963-8.
17. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. *Arch Intern Med* 2000;160(22):3415-20.
18. Cohen AT, Alikhan R, Arcelus JI, et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. *Thromb Haemost* 2005;94(4):750-9.
19. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. *Circulation* 2003;107(23 Suppl 1):I9-16.
20. Jang MJ, Bang SM, Oh D. Incidence of venous thromboembolism in Korea: from the Health Insurance Review and Assessment Service database. *J Thromb Haemost* 2011;9(1):85-91.
21. Kyrle PA, Eichinger S. Deep vein thrombosis. *Lancet* 2005;365(9465):1163-74.
22. Meignan M, Rosso J, Gauthier H, et al. Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis. *Arch Intern Med* 2000;160(2):159-64.
23. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? *J R Soc Med* 1989;82(4):203-5.
24. Murin S, Romano PS, White RH. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. *Thromb Haemost* 2002;88(3):407-14.
25. Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. *J Thromb Haemost* 2007;5(4):692-9.
26. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Massive pulmonary embolism. *Circulation* 2006;113(4):577-82.
27. Heit JA. The epidemiology of venous thromboembolism in the community. *Arterioscler Thromb Vasc Biol* 2008;28(3):370-2.
28. Guijarro R, Montes J, Sanroman C, et al. Venous thromboembolism in Spain. Comparison between an administrative database and the RIETE registry. *Eur J Intern Med* 2008;19(6):443-6.
29. Spencer FA, Emery C, Joffe SW, et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. *J Thromb Thrombolysis* 2009;28(4):401-9.
30. Kakkar VV, Howe CT, Flanc C, Clarke MB. Natural history of post-operative deep-vein thrombosis. *Lancet* 1969;2(7614):230-2.
31. Galanaud JP, Sevestre MA, Genty C, et al. Incidence and predictors of venous thromboembolism recurrence after a first isolated distal deep vein thrombosis. *J Thromb Haemost* 2014;12(4):436-43.
32. Wang CJ, Wang JW, Chen LM, et al. Deep vein thrombosis after total knee arthroplasty. *J Formos Med Assoc* 2000;99(11):848-53.
33. Cogo A, Lensing AW, Prandoni P, Hirsh J. Distribution of thrombosis in patients with symptomatic deep vein thrombosis. Implications for simplifying the diagnostic process with compression ultrasound. *Arch Intern Med* 1993;153(24):2777-80.
34. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. *Thromb Haemost* 2000;83(5):657-60.
35. Ho WK, Hankey GJ, Eikelboom JW. The incidence of venous thromboembolism: a prospective, community-based study in Perth, Western Australia. *Med J Aust* 2008;189(3):144-7.
36. Liao S, Woulfe T, Hyder S, et al. Incidence of venous thromboembolism in different ethnic groups: a regional direct comparison study. *J Thromb Haemost* 2014;12(2):214-9.
37. White RH, Zhou H, Murin S, Harvey D. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. *Thromb Haemost* 2005;93(2):298-305.
38. Cohen A, Chiu KM, Park K, et al. Managing venous thromboembolism in Asia: winds of change in the era of new oral anticoagulants. *Thromb Res* 2012;130(3):291-301.
39. Lee CH, Cheng CL, Lin LJ, et al. Epidemiology and predictors of short-term mortality in symptomatic venous thromboembolism. *Circ J* 2011;75(8):1998-2004.
40. Angchaisuksiri P. Venous thromboembolism in Asia--an unrecognized and under-treated problem? *Thromb Haemost* 2011;106(4):585-90.
41. Yu YB, Gau JP, Liu CY, et al. A nation-wide analysis of venous thromboembolism in 497,180 cancer patients with the development and validation of a risk-stratification scoring system. *Thromb Haemost* 2012;108(2):225-35.
42. Anderson FA Jr, Wheeler HB. Physician practices in the management of venous thromboembolism: a community-wide survey. *J Vasc Surg* 1992;16(5):707-14.
43. Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. *Lancet* 2010;376(9757):2032-9.
44. Goldhaber SZ. Venous thromboembolism: epidemiology and magnitude of the problem. *Best Pract Res Clin Haematol* 2012;25(3):235-42.
45. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. *Lancet* 2012;379(9828):1835-46.
46. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest

- Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;141(2 Suppl):e278S-325S.
47. Bjornara BT, Gudmundsen TE, Dahl OE. Frequency and timing of clinical venous thromboembolism after major joint surgery. *J Bone Joint Surg Br* 2006;88(3):386-91.
 48. Bergqvist D, Benoni G, Bjorgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. *N Engl J Med* 1996;335(10):696-700.
 49. Lee WS, Kim KI, Lee HJ, et al. The incidence of pulmonary embolism and deep vein thrombosis after knee arthroplasty in Asians remains low: a meta-analysis. *Clin Orthop Relat Res* 2013;471(5):1523-32.
 50. Chung LH, Chen WM, Chen CF, et al. Deep vein thrombosis after total knee arthroplasty in asian patients without prophylactic anticoagulation. *Orthopedics* 2011;34(1):15.
 51. Cohen AT, Asia-Pacific Thrombosis Advisory B. Asia-Pacific Thrombosis Advisory Board consensus paper on prevention of venous thromboembolism after major orthopaedic surgery. *Thromb Haemost* 2010;104(5):919-30.
 52. Liew NC, Chang YH, Choi G, et al. Asian venous thromboembolism guidelines: prevention of venous thromboembolism. *Int Angiol* 2012;31(6):501-16.
 53. Leizorovicz A, Turpie AG, Cohen AT, et al. Epidemiology of venous thromboembolism in Asian patients undergoing major orthopedic surgery without thromboprophylaxis. The SMART study. *J Thromb Haemost* 2005;3(1):28-34.
 54. Leizorovicz A, Committee SVSS. Epidemiology of post-operative venous thromboembolism in Asian patients. Results of the SMART venography study. *Haematologica* 2007;92(9):1194-200.
 55. Piovella F, Wang CJ, Lu H, et al. Deep-vein thrombosis rates after major orthopedic surgery in Asia. An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography. *J Thromb Haemost* 2005;3(12):2664-70.
 56. Lee CH, Cheng CL, Chang CH, et al. Universal pharmacological thromboprophylaxis for total knee arthroplasty may not be necessary in low-risk populations: a nationwide study in Taiwan. *J Thromb Haemost* 2012;10(1):56-63.
 57. Wu PK, Chen CF, Chung LH, et al. Population-based epidemiology of postoperative venous thromboembolism in Taiwanese patients receiving hip or knee arthroplasty without pharmacological thromboprophylaxis. *Thromb Res* 2014;133(5):719-24.
 58. Wang CJ, Wang JW, Weng LH, et al. Clinical significance of muscular deep-vein thrombosis after total knee arthroplasty. *Chang Gung Med J* 2007;30(1):41-6.
 59. Attia J, Ray JG, Cook DJ, et al. Deep vein thrombosis and its prevention in critically ill adults. *Thromb Res* 2001;161(10):1268-79.
 60. Turpie AG. Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. *Am J Cardiol* 2000;86(12B):48M-52M.
 61. Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. *Circulation* 2004;110(7):874-9.
 62. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. *BMJ* 2006;332(7537):325-9.
 63. Leung V, Leung V, Lui W, et al. Incidence of deep vein thrombosis in hospitalized Chinese medical patients is similar to that in western populations. *Thromb Res* 2006;118(6):763-4.
 64. Dunn AS, Brenner A, Halm EA. The magnitude of an iatrogenic disorder: a systematic review of the incidence of venous thromboembolism for general medical inpatients. *Thromb Haemost* 2006;95(5):758-62.
 65. Nakamura M, Fujioka H, Yamada N, et al. Clinical characteristics of acute pulmonary thromboembolism in Japan: results of a multicenter registry in the Japanese Society of Pulmonary Embolism Research. *Clin Cardiol* 2001;24(2):132-8.
 66. Chau KY, Yuen ST, Wong MP. Clinicopathological pattern of pulmonary thromboembolism in Chinese autopsy patients: comparison with Caucasian series. *Pathology* 1997;29(3):263-6.
 67. Dickens P, Knight BH, Ip P, Fung WS. Fatal pulmonary embolism: a comparative study of autopsy incidence in Hong Kong and Cardiff, Wales. *Forensic Sci Int* 1997;90(3):171-4.
 68. Zakai NA, McClure LA. Racial differences in venous thromboembolism. *J Thromb Haemost* 2011;9(10):1877-82.
 69. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. *N Engl J Med* 2001;344(16):1222-31.
 70. Margaglione M, Grandone E. Population genetics of venous thromboembolism. A narrative review. *Thromb Haemost* 2011;105(2):221-31.
 71. De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. *Haematologica* 2002;87(10):1095-108.
 72. Shen MC, Lin JS, Tsay W. High prevalence of antithrombin III, protein C and protein S deficiency, but no factor V Leiden mutation in venous thrombophilic Chinese patients in Taiwan. *Thromb Res* 1997;87(4):377-85.
 73. Ho CH, Chau WK, Hsu HC, et al. Causes of venous thrombosis in fifty Chinese patients. *Am J Hematol* 2000;63(2):74-8.
 74. Shen MC, Lin JS, Tsay W. Protein C and protein S deficiencies are the most important risk factors associated with thrombosis in Chinese venous thrombophilic patients in Taiwan. *Thromb Res* 2000;99(5):447-52.
 75. Chen TY, Su WC, Tsao CJ. Incidence of thrombophilia detected in southern Taiwanese patients with venous thrombosis. *Ann Hematol* 2003;82(2):114-7.
 76. Goldhaber SZ. Risk factors for venous thromboembolism. *J Am Coll Cardiol* 2010;56(1):1-7.
 77. De Stefano V, Rossi E. Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. A review of the

- Guidelines from Scientific Societies and Working Groups. *Thromb Haemost* 2013;110(4):697-705.
78. Chong LY, Fenu E, Stansby G, Hodgkinson S, Guideline Development G. Management of venous thromboembolic diseases and the role of thrombophilia testing: summary of NICE guidance. *BMJ* 2012;344:e3979.
 79. Howard LS, Hughes RJ. NICE guideline: management of venous thromboembolic diseases and role of thrombophilia testing. *Thorax* 2013;68(4):391-3.
 80. Hull R, Hirsh J, Sackett DL, et al. Clinical validity of a negative venogram in patients with clinically suspected venous thrombosis. *Circulation* 1981;64(3):622-5.
 81. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. *Circulation* 1996;93(12):2212-45.
 82. Elias A, Mallard L, Elias M, et al. A single complete ultrasound investigation of the venous network for the diagnostic management of patients with a clinically suspected first episode of deep venous thrombosis of the lower limbs. *Thromb Haemost* 2003;89(2):221-7.
 83. Grune S, Orlik J, Von Korn H, et al. Clinical signs in the diagnosis of deep vein thrombosis. *Int Angiol* 2011;30(1):64-70.
 84. Wells PS, Hirsh J, Anderson DR, et al. Accuracy of clinical assessment of deep-vein thrombosis. *Lancet* 1995;345(8961):1326-30.
 85. Heijboer H, Buller HR, Lensing AW, et al. A comparison of real-time compression ultrasonography with impedance plethysmography for the diagnosis of deep-vein thrombosis in symptomatic outpatients. *N Engl J Med* 1993;329(19):1365-9.
 86. Lensing AW, Buller HR, Prandoni P, et al. Contrast venography, the gold standard for the diagnosis of deep-vein thrombosis: improvement in observer agreement. *Thromb Haemost* 1992;67(1):8-12.
 87. Bates SM, Jaeschke R, Stevens SM, et al. Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;141(2 Suppl):e351S-418S.
 88. Constans J, Nelzy ML, Salmi LR, et al. Clinical prediction of lower limb deep vein thrombosis in symptomatic hospitalized patients. *Thromb Haemost* 2001;86(4):985-90.
 89. Kahn SR, Joseph L, Abenham L, Leclerc JR. Clinical prediction of deep vein thrombosis in patients with leg symptoms. *Thromb Haemost* 1999;81(3):353-7.
 90. Buller HR, Ten Cate-Hoek AJ, Hoes AW, et al. Safely ruling out deep venous thrombosis in primary care. *Ann Intern Med* 2009;150(4):229-35.
 91. Goodacre S, Sutton AJ, Sampson FC. Meta-analysis: the value of clinical assessment in the diagnosis of deep venous thrombosis. *Ann Intern Med* 2005;143(2):129-39.
 92. Wells PS, Anderson DR, Bormanis J, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. *Lancet* 1997;350(9094):1795-8.
 93. Wells PS, Owen C, Doucette S, et al. Does this patient have deep vein thrombosis? *JAMA* 2006;295(2):199-207.
 94. Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. *N Engl J Med* 2003;349(13):1227-35.
 95. Cornuz J, Ghali WA, Hayoz D, et al. Clinical prediction of deep venous thrombosis using two risk assessment methods in combination with rapid quantitative D-dimer testing. *Am J Med* 2002;112(3):198-203.
 96. Yamaki T, Nozaki M, Sakurai H, et al. Combined use of pretest clinical probability score and latex agglutination D-dimer testing for excluding acute deep vein thrombosis. *J Vasc Surg* 2009;50(5):1099-105.
 97. Righini M, Perrier A, De Moerloose P, Bounameaux H. D-Dimer for venous thromboembolism diagnosis: 20 years later. *J Thromb Haemost* 2008;6(7):1059-71.
 98. Huisman MV, Klok FA. Diagnostic management of acute deep vein thrombosis and pulmonary embolism. *J Thromb Haemost* 2013;11(3):412-22.
 99. Di Nisio M, Squizzato A, Rutjes AW, et al. Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. *J Thromb Haemost* 2007;5(2):296-304.
 100. Righini M, Goehring C, Bounameaux H, Perrier A. Effects of age on the performance of common diagnostic tests for pulmonary embolism. *Am J Med* 2000;109(5):357-61.
 101. Douma RA, le Gal G, Sohne M, et al. Potential of an age adjusted D-dimer cut-off value to improve the exclusion of pulmonary embolism in older patients: a retrospective analysis of three large cohorts. *BMJ* 2010;340:c1475.
 102. Schouten HJ, Geersing GJ, Koek HL, et al. Diagnostic accuracy of conventional or age adjusted D-dimer cut-off values in older patients with suspected venous thromboembolism: systematic review and meta-analysis. *BMJ* 2013;346:f2492.
 103. Righini M, Van Es J, Den Exter PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. *JAMA* 2014;311(11):1117-24.
 104. Goodacre S, Sampson F, Thomas S, et al. Systematic review and meta-analysis of the diagnostic accuracy of ultrasonography for deep vein thrombosis. *BMC Med Imaging* 2005;5:6.
 105. Wells PS, Lensing AW, Davidson BL, et al. Accuracy of ultrasound for the diagnosis of deep venous thrombosis in asymptomatic patients after orthopedic surgery. A meta-analysis. *Ann Intern Med* 1995;122(1):47-53.
 106. Kearon C, Julian JA, Newman TE, Ginsberg JS. Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. *Ann Intern Med* 1998;128(8):663-77.
 107. Gottlieb RH, Widjaja J, Tian L, et al. Calf sonography for detecting deep venous thrombosis in symptomatic patients: experience and review of the literature. *J Clin Ultrasound* 1999;27(8):415-20.
 108. Cogo A, Lensing AW, Koopman MM, et al. Compression

- ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. *BMJ* 1998;316(7124):17-20.
109. Ten Wolde M, Hagen PJ, Macgillivray MR, et al. Non-invasive diagnostic work-up of patients with clinically suspected pulmonary embolism; results of a management study. *J Thromb Haemost* 2004;2(7):1110-7.
 110. Kanne JP, Lalani TA. Role of computed tomography and magnetic resonance imaging for deep venous thrombosis and pulmonary embolism. *Circulation* 2004;109(12 Suppl 1):I15-21.
 111. Bruce D, Loud PA, Klippenstein DL, et al. Combined CT venography and pulmonary angiography: how much venous enhancement is routinely obtained? *AJR Am J Roentgenol* 2001;176(5):1281-5.
 112. Garg K, Kemp JL, Wojcik D, et al. Thromboembolic disease: comparison of combined CT pulmonary angiography and venography with bilateral leg sonography in 70 patients. *AJR Am J Roentgenol* 2000;175(4):997-1001.
 113. Rademaker J, Griesshaber V, Hidajat N, et al. Combined CT pulmonary angiography and venography for diagnosis of pulmonary embolism and deep vein thrombosis: radiation dose. *J Thorac Imaging* 2001;16(4):297-9.
 114. Reichert M, Henzler T, Krissak R, et al. Venous thromboembolism: additional diagnostic value and radiation dose of pelvic CT venography in patients with suspected pulmonary embolism. *Eur J Radiol* 2011;80(1):50-3.
 115. Thomas SM, Goodacre SW, Sampson FC, van Beek EJ. Diagnostic value of CT for deep vein thrombosis: results of a systematic review and meta-analysis. *Clin Radiol* 2008;63(3):299-304.
 116. Sampson FC, Goodacre SW, Thomas SM, van Beek EJ. The accuracy of MRI in diagnosis of suspected deep vein thrombosis: systematic review and meta-analysis. *Eur Radiol* 2007;17(1):175-81.
 117. Dupas B, el Kouri D, Curtet C, et al. Angiomagnetic resonance imaging of iliofemorocaval venous thrombosis. *Lancet* 1995;346(8966):17-9.
 118. Kearon C. Natural history of venous thromboembolism. *Circulation* 2003;107(23 Suppl 1):I22-30.
 119. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. *Ann Intern Med* 1996;125(1):1-7.
 120. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;141(2 Suppl):e419S-94S.
 121. Prandoni P, Lensing AW, Prins MH, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. *Ann Intern Med* 2002;137(12):955-60.
 122. Prandoni P, Prins MH, Lensing AW, et al. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. *Ann Intern Med* 2009;150(9):577-85.
 123. Enden T, Klow NE, Sandvik L, et al. Catheter-directed thrombolysis vs. anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short-term patency. *J Thromb Haemost* 2009;7(8):1268-75.
 124. Hull RD, Marder VJ, Mah AF, et al. Quantitative assessment of thrombus burden predicts the outcome of treatment for venous thrombosis: a systematic review. *Am J Med* 2005;118(5):456-64.
 125. de Wolf MA, Wittens CH, Kahn SR. Incidence and risk factors of the post-thrombotic syndrome. *Phlebology* 2012;27(Suppl 1):85-94.
 126. Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. *Circulation* 2011;123(16):1788-830.
 127. Enden T, Haig Y, Klow NE, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. *Lancet* 2012;379(9810):31-8.
 128. Watson L, Broderick C, Armon MP. Thrombolysis for acute deep vein thrombosis. *Cochrane Database Syst Rev* 2014;1:CD002783.
 129. Sharifi M, Bay C, Mehdipour M, et al. Thrombus Obliteration by Rapid Percutaneous Endovenous Intervention in Deep Venous Occlusion (TORPEDO) trial: midterm results. *J Endovasc Ther* 2012;19(2):273-80.
 130. Vedantham S, Goldhaber SZ, Kahn SR, et al. Rationale and design of the ATTRACT Study: a multicenter randomized trial to evaluate pharmacomechanical catheter-directed thrombolysis for the prevention of postthrombotic syndrome in patients with proximal deep vein thrombosis. *Am Heart J* 2013;165(4):523-30.e3.
 131. Brandjes DP, Heijboer H, Buller HR, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. *N Engl J Med* 1992;327(21):1485-9.
 132. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. *Ann Intern Med* 1993;119(9):874-81.
 133. Cossette B, Pelletier ME, Carrier N, et al. Evaluation of bleeding risk in patients exposed to therapeutic unfractionated or low-molecular-weight heparin: a cohort study in the context of a quality improvement initiative. *Ann Pharmacother* 2010;44(6):994-1002.
 134. Prandoni P, Siragusa S, Girolami B, et al. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. *Blood* 2005;106(9):3049-54.
 135. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. *Lancet* 1992;340(8824):873-6.

136. Palareti G, Legnani C, Cosmi B, et al. Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. *J Thromb Haemost* 2005;3(5):955-61.
137. van Dongen CJ, Prandoni P, Frulla M, et al. Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. *J Thromb Haemost* 2005;3(5):939-42.
138. Haas S. New oral Xa and IIa inhibitors: updates on clinical trial results. *J Thromb Thrombolysis* 2008;25(1):52-60.
139. Investigators E, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. *N Engl J Med* 2010;363(26):2499-510.
140. Investigators E-P, Buller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. *N Engl J Med* 2012;366(14):1287-97.
141. Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. *Thromb J* 2013;11(1):21.
142. Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. *Circulation* 2014;129(7):764-72.
143. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. *N Engl J Med* 2009;361(24):2342-52.
144. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. *N Engl J Med* 2013;369(9):799-808.
145. Hokusai VTEI, Buller HR, Decousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. *N Engl J Med* 2013;369(15):1406-15.
146. Verhamme P, Bounameaux H. Direct oral anticoagulants for acute venous thromboembolism: closing the circle? *Circulation* 2014;129(7):725-7.
147. Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. *Thromb Haemost* 2014;111(5):789-97.
148. Wang KL, Chiang CE. Optimal international normalized ratio for atrial fibrillation in Asians and Japanese: do we really know? *Circ J* 2013;77(9):2242-3.
149. Lip GY, Wang KL, Chiang CE. Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal. *Int J Cardiol* 2015;180:246-54.
150. Nakamura M, Wang YQ, Wang C, et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a sub-analysis of East Asian patients in the Hokusai-VTE trial. *J Thromb Haemost* 2015;13(9):1606-14.
151. Wang Y, Wang C, Chen Z, et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. *Thromb J* 2013;11(1):25.
152. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. *N Engl J Med* 1999;340(12):901-7.
153. Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. *N Engl J Med* 1979;301(16):855-8.
154. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. *N Engl J Med* 1995;332(25):1661-5.
155. Kaatz S, Fu AC, AbuDagga A, et al. Association between anticoagulant treatment duration and risk of venous thromboembolism recurrence and bleeding in clinical practice. *Thromb Res* 2014;134(4):807-13.
156. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. *Arch Intern Med* 2000;160(6):761-8.
157. Schulman S, Lindmarker P, Holmstrom M, et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. *J Thromb Haemost* 2006;4(4):734-42.
158. Agnelli G, Becattini C. Treatment of DVT: how long is enough and how do you predict recurrence. *J Thromb Thrombolysis* 2008;25(1):37-44.
159. Nijkeuter M, Sohne M, Tick LW, et al. The natural course of hemodynamically stable pulmonary embolism: Clinical outcome and risk factors in a large prospective cohort study. *Chest* 2007;131(2):517-23.
160. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. *N Engl J Med* 2001;345(3):165-9.
161. Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. *Circulation* 2001;103(20):2453-60.
162. Heit JA. Predicting the risk of venous thromboembolism recurrence. *Am J Hematol* 2012;87(Suppl 1):S63-7.
163. Kyrle PA, Minar E, Bialonczyk C, et al. The risk of recurrent venous thromboembolism in men and women. *N Engl J Med* 2004;350(25):2558-63.
164. Eichinger S, Hron G, Bialonczyk C, et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. *Arch Intern Med* 2008;168(15):1678-83.
165. Eichinger S, Pecheniuk NM, Hron G, et al. High-density lipoprotein and the risk of recurrent venous thromboembolism. *Circulation* 2007;115(12):1609-14.
166. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. *Arch Intern Med* 2000;160(6):769-74.
167. Iorio A, Kearon C, Filippucci E, et al. Risk of recurrence after a

- first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. *Arch Intern Med* 2010;170(19):1710-6.
168. Agnelli G, Prandoni P, Becattini C, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. *Ann Intern Med* 2003;139(1):19-25.
 169. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. *N Engl J Med* 2003;348(15):1425-34.
 170. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. *N Engl J Med* 2003;349(7):631-9.
 171. Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. *N Engl J Med* 2013;368(8):709-18.
 172. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. *N Engl J Med* 2013;368(8):699-708.
 173. Hovens MM, Snoep JD, Tamsma JT, Huisman MV. Aspirin in the prevention and treatment of venous thromboembolism. *J Thromb Haemost* 2006;4(7):1470-5.
 174. Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. *N Engl J Med* 2012;367(21):1979-87.
 175. Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. *N Engl J Med* 2012;366(21):1959-67.
 176. Simes J, Becattini C, Agnelli G, et al. Aspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration. *Circulation* 2014;130(13):1062-71.
 177. Goldhaber SZ. Prevention of recurrent idiopathic venous thromboembolism. *Circulation* 2004;110(24 Suppl 1):IV20-4.
 178. Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. *Arterioscler Thromb Vasc Biol* 2009;29(3):298-310.
 179. Eichinger S, Heinze G, Jandek LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. *Circulation* 2010;121(14):1630-6.
 180. Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). *J Thromb Haemost* 2012;10(6):1019-25.
 181. Ruiz-Gimenez N, Suarez C, Gonzalez R, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. *Thromb Haemost* 2008;100(1):26-31.
 182. Eichinger S, Weltermann A, Philipp K, et al. Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden. *Thromb Haemost* 1999;82(4):1232-6.
 183. Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. *Ann Intern Med* 2005;143(10):697-706.
 184. Sultan AA, Tata LJ, West J, et al. Risk factors for first venous thromboembolism around pregnancy: a population-based cohort study from the United Kingdom. *Blood* 2013;121(19):3953-61.
 185. Liu S, Rouleau J, Joseph KS, et al. Epidemiology of pregnancy-associated venous thromboembolism: a population-based study in Canada. *J Obstet Gynaecol Can* 2009;31(7):611-20.
 186. Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. *J Thromb Haemost* 2008;6(4):632-7.
 187. Chan WS, Spencer FA, Ginsberg JS. Anatomic distribution of deep vein thrombosis in pregnancy. *CMAJ* 2010;182(7):657-60.
 188. Kawaguchi S, Yamada T, Takeda M, et al. Changes in d-dimer levels in pregnant women according to gestational week. *Pregnancy Hypertens* 2013;3(3):172-7.
 189. Le Gal G, Kercret G, Ben Yahmed K, et al. Diagnostic value of single complete compression ultrasonography in pregnant and postpartum women with suspected deep vein thrombosis: prospective study. *BMJ* 2012;344:e2635.
 190. Eskandari MK, Sugimoto H, Richardson T, et al. Is color-flow duplex a good diagnostic test for detection of isolated calf vein thrombosis in high-risk patients? *Angiology* 2000;51(9):705-10.
 191. Ralli E, Zezza L, Caserta D. Pregnancy and venous thromboembolism. *Curr Opin Obstet Gynecol* 2014;26(6):469-75.
 192. Chan WS, Rey E, Kent NE, et al. Venous thromboembolism and antithrombotic therapy in pregnancy. *J Obstet Gynaecol Can* 2014;36(6):527-53.
 193. Marik PE, Plante LA. Venous thromboembolic disease and pregnancy. *N Engl J Med* 2008;359(19):2025-33.
 194. Chan WS, Spencer FA, Lee AY, et al. Safety of withholding anticoagulation in pregnant women with suspected deep vein thrombosis following negative serial compression ultrasound and iliac vein imaging. *CMAJ* 2013;185(4):E194-200.
 195. Romualdi E, Dentali F, Rancan E, et al. Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature. *J Thromb Haemost* 2013;11(2):270-81.
 196. Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;141(2 Suppl):e691S-736S.
 197. European Society of G, Association for European Paediatric C, German Society for Gender M, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). *Eur Heart J* 2011;32(24):3147-97.
 198. Brill-Edwards P, Ginsberg JS, Gent M, et al. Safety of withholding

- heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. *N Engl J Med* 2000;343(20):1439-44.
199. Bauersachs RM, Dudenhausen J, Faridi A, et al. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. *Thromb Haemost* 2007;98(6):1237-45.
200. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. *Circulation* 2003;107(23 Suppl 1):117-21.
201. Schulman S, Zondag M, Linkins L, et al. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. *J Thromb Haemost* 2015;13(6):1010-8.
202. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. *N Engl J Med* 2000;343(25):1846-50.
203. Bura A, Cailleux N, Bienvenu B, et al. Incidence and prognosis of cancer associated with bilateral venous thrombosis: a prospective study of 103 patients. *J Thromb Haemost* 2004;2(3):441-4.
204. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. *Blood* 2002;100(10):3484-8.
205. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. *N Engl J Med* 2003;349(2):146-53.
206. Lee AY, Kamphuisen PW, Meyer G, et al. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. *JAMA* 2015;314(7):677-86.
207. Schulman S, Goldhaber SZ, Kearon C, et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. *Thromb Haemost* 2015;114(1):150-7.
208. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. *J Thromb Haemost* 2015;13(12):2187-91.
209. Larsen TB, Nielsen PB, Skjoth F, et al. Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes. *PLoS One* 2014;9(12):e114445.
210. Posch F, Konigsbrugge O, Zielinski C, et al. Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. *Thromb Res* 2015;136(3):582-9.
211. Carrier M, Cameron C, Delluc A, et al. Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. *Thromb Res* 2014;134(6):1214-9.
212. Akl EA, Kahale L, Barba M, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. *Cochrane Database Syst Rev* 2014;7:CD006650.
213. Francis CW, Kessler CM, Goldhaber SZ, et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. *J Thromb Haemost* 2015;13(6):1028-35.
214. van Es N, Di Nisio M, Bleker SM, et al. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. *Thromb Haemost* 2015;114(6):1268-76.
215. Hudson KL, Collins FS. Sharing and reporting the results of clinical trials. *JAMA* 2015;313(4):355-6.
216. Jones CW, Handler L, Crowell KE, et al. Non-publication of large randomized clinical trials: cross sectional analysis. *BMJ* 2013;347:f6104.